Dianthus Therapeutics, Inc. $DNTH Shares Purchased by Vanguard Group Inc.

Posted by Francis Steltz on May 14th, 2026

Vanguard Group Inc. increased its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report) by 24.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,048,452 shares of the company’s stock after purchasing an additional 406,254 shares during the quarter. Vanguard Group Inc.’s holdings in Dianthus Therapeutics were worth $84,417,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Raymond James Financial Inc. acquired a new stake in shares of Dianthus Therapeutics during the 2nd quarter worth about $27,000. Parkside Financial Bank & Trust increased its position in shares of Dianthus Therapeutics by 131.7% during the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after purchasing an additional 540 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Dianthus Therapeutics during the 3rd quarter worth about $64,000. Tower Research Capital LLC TRC increased its position in shares of Dianthus Therapeutics by 330.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after purchasing an additional 3,317 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Dianthus Therapeutics during the 4th quarter worth about $135,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Price Performance

NASDAQ DNTH opened at $85.74 on Thursday. The stock has a 50-day moving average of $83.62 and a two-hundred day moving average of $57.77. The company has a market cap of $4.69 billion, a P/E ratio of -20.76 and a beta of 1.18. Dianthus Therapeutics, Inc. has a 1-year low of $16.64 and a 1-year high of $96.50.

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.22. The business had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. On average, analysts anticipate that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on DNTH shares. Oppenheimer raised their price objective on Dianthus Therapeutics to $145.00 and gave the stock an “outperform” rating in a research report on Monday, March 9th. Truist Financial raised their price objective on Dianthus Therapeutics from $63.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, March 9th. Wedbush lifted their target price on Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. Wolfe Research initiated coverage on Dianthus Therapeutics in a research report on Thursday, April 9th. They issued an “outperform” rating and a $98.00 target price for the company. Finally, William Blair reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a research report on Monday, March 16th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $117.82.

Check Out Our Latest Stock Report on Dianthus Therapeutics

Insider Buying and Selling

In other news, CAO Edward Carr sold 43,682 shares of Dianthus Therapeutics stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.49, for a total value of $3,559,646.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Simrat Randhawa sold 33,830 shares of Dianthus Therapeutics stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $81.48, for a total value of $2,756,468.40. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 323,021 shares of company stock worth $26,564,008. 3.02% of the stock is owned by corporate insiders.

About Dianthus Therapeutics

(Free Report)

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.